Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. (2019)
Attributed to:
Is targeting vascular remodelling by filarial parasites a viable anti-morbidity solution?
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aau2086
PubMed Identifier: 30867321
Publication URI: http://europepmc.org/abstract/MED/30867321
Type: Journal Article/Review
Volume: 11
Parent Publication: Science translational medicine
Issue: 483
ISSN: 1946-6234